{"nctId":"NCT03999996","briefTitle":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose","startDateStruct":{"date":"2019-11-12","type":"ACTUAL"},"conditions":["Dengue Fever"],"count":365,"armGroups":[{"label":"Prior to Booster: DEN-304","type":"EXPERIMENTAL","interventionNames":["Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)"]},{"label":"Prior to Booster: DEN-315","type":"EXPERIMENTAL","interventionNames":["Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)"]},{"label":"Booster Phase: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"Booster Phase: TDV","type":"EXPERIMENTAL","interventionNames":["Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)"]}],"interventions":[{"name":"Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Male or female participants (irrespective of serostatus at baseline in the parent trials (DEN-304 \\[(NCT03423173)\\] and DEN-315 \\[NCT03341637\\]) who received at least one dose of Takeda's tetravalent dengue vaccine candidate (TDV) in the parent trials and have data from at least one blood draw post-vaccination.\n\nExclusion Criteria:\n\n1. Participants with a prolonged period of habitation (≥1 year) in a dengue endemic area within the 2 years prior to Visit 1 Day 1 (Month 0).\n2. Previous and planned vaccination (during the trial conduct), against any flavivirus including dengue (other than Takeda's TDV), yellow fever (YF), Japanese encephalitis (JE) viruses or tick-borne encephalitis.\n\nBooster Exclusion Criteria:\n\n1. Participants for whom baseline serostatus is not defined in the parent trials (DEN-304 \\[(NCT03423173)\\] and DEN-315 \\[NCT03341637\\]).\n2. Participants with any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (eg, Guillain-Barré syndrome).\n3. Known or suspected impairment/alteration of immune function, including:\n\n   1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US); use of inhaled, intranasal, or topical corticosteroids is allowed.\n   2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US).\n   3. Administration of immunoglobulins and/or any blood products within the 3 months prior to administration of the TDV booster or placebo at Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US); consider whether applicable as an exclusion criterion or criterion for delay.\n   4. Receipt of immunostimulants within 60 days prior to Month 42 for participants from parent trial DEN-315 (Mexico)/ Month 15 for participants from parent trial DEN-304 (US).\n   5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Month 42 for participants from parent trial DEN-315 (Mexico) / Month 15 for participants from parent trial DEN-304 (US).\n   6. Known human immunodeficiency virus (HIV) infection or HIV-related disease.\n   7. Hepatitis C virus infection.\n   8. Genetic immunodeficiency.\n4. Abnormalities of splenic or thymic function.\n5. Participants with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.\n6. Participants with history of current or previous infection with a flavivirus such as dengue, Zika, YF, JE, West Nile fever, tick-borne encephalitis or Murray Valley encephalitis and participants with a prolonged period of habitation (≥1 year) in a dengue endemic area during trial conduct.","healthyVolunteers":true,"sex":"ALL","minimumAge":"13 Years","maximumAge":"63 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":null},{"groupId":"OG001","value":"88.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"539.6","spread":null},{"groupId":"OG001","value":"425.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":null},{"groupId":"OG001","value":"96.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"427.3","spread":null},{"groupId":"OG001","value":"276.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"25.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"22.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"560.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3 at Month 42 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 (Month 0 [Day 1])","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.8","spread":null},{"groupId":"OG001","value":"259.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"560.1","spread":null},{"groupId":"OG001","value":"714.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null},{"groupId":"OG001","value":"118.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"112.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"536.4","spread":null},{"groupId":"OG001","value":"410.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":null},{"groupId":"OG001","value":"24.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"544.5","spread":null},{"groupId":"OG001","value":"272.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null},{"groupId":"OG001","value":"34.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"411.1","spread":null},{"groupId":"OG001","value":"276.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"214.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"484.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"573.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3 at Month 42 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"79.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"76.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity Rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 [Month 0 (Day 1])","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null},{"groupId":"OG001","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for participants from both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"73.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"82.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) ((DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"67.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"22.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 1 (Month 0 [Day 1])","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 1 at Month 0 for both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 2 (Month 12)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 2 at Month 12 for both parent trials (DEN-304 and DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"65.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. (DEN-304). All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 15 for parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes in the Period Prior to Booster by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3 at Month 42 for parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116.2","spread":null},{"groupId":"OG001","value":"120.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"404.0","spread":null},{"groupId":"OG001","value":"361.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":null},{"groupId":"OG001","value":"30.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"21.4","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110.8","spread":null},{"groupId":"OG001","value":"1438.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"363.4","spread":null},{"groupId":"OG001","value":"1038.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"446.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"273.5","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126.4","spread":null},{"groupId":"OG001","value":"130.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"583.9","spread":null},{"groupId":"OG001","value":"596.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.1","spread":null},{"groupId":"OG001","value":"1254.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"499.2","spread":null},{"groupId":"OG001","value":"1121.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"389.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"260.9","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.6","spread":null},{"groupId":"OG001","value":"106.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233.5","spread":null},{"groupId":"OG001","value":"165.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"1795.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227.5","spread":null},{"groupId":"OG001","value":"917.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"556.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"295.3","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165.0","spread":null},{"groupId":"OG001","value":"310.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"353.6","spread":null},{"groupId":"OG001","value":"771.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"88.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.4","spread":null},{"groupId":"OG001","value":"106.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"411.9","spread":null},{"groupId":"OG001","value":"326.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.5","spread":null},{"groupId":"OG001","value":"1192.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264.2","spread":null},{"groupId":"OG001","value":"1533.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null},{"groupId":"OG001","value":"286.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null},{"groupId":"OG001","value":"204.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.4","spread":null},{"groupId":"OG001","value":"1473.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379.8","spread":null},{"groupId":"OG001","value":"988.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"472.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"283.9","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.5","spread":null},{"groupId":"OG001","value":"368.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368.8","spread":null},{"groupId":"OG001","value":"839.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"102.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.6","spread":null},{"groupId":"OG001","value":"109.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"639.0","spread":null},{"groupId":"OG001","value":"562.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"26.5","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.6","spread":null},{"groupId":"OG001","value":"1124.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264.3","spread":null},{"groupId":"OG001","value":"1545.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null},{"groupId":"OG001","value":"239.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"202.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.2","spread":null},{"groupId":"OG001","value":"1275.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"559.8","spread":null},{"groupId":"OG001","value":"1067.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"420.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"271.1","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"470.4","spread":null},{"groupId":"OG001","value":"185.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307.1","spread":null},{"groupId":"OG001","value":"598.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151.1","spread":null},{"groupId":"OG001","value":"58.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null},{"groupId":"OG001","value":"101.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"228.5","spread":null},{"groupId":"OG001","value":"148.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"12.3","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"427.0","spread":null},{"groupId":"OG001","value":"1393.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264.1","spread":null},{"groupId":"OG001","value":"1502.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180.8","spread":null},{"groupId":"OG001","value":"464.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null},{"groupId":"OG001","value":"208.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"1836.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"224.8","spread":null},{"groupId":"OG001","value":"878.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"565.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"304.5","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5, 6 months post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"464.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305.2","spread":null},{"groupId":"OG001","value":"552.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"159.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.8","spread":null},{"groupId":"OG001","value":"410.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"433.0","spread":null},{"groupId":"OG001","value":"689.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null},{"groupId":"OG001","value":"133.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"89.2","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null},{"groupId":"OG001","value":"553.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187.0","spread":null},{"groupId":"OG001","value":"403.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"205.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"85.0","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166.2","spread":null},{"groupId":"OG001","value":"435.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278.9","spread":null},{"groupId":"OG001","value":"699.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"137.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"83.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"469.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"308.4","spread":null},{"groupId":"OG001","value":"533.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"163.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154.2","spread":null},{"groupId":"OG001","value":"461.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"337.6","spread":null},{"groupId":"OG001","value":"825.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"145.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":null},{"groupId":"OG001","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.6","spread":null},{"groupId":"OG001","value":"401.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"451.4","spread":null},{"groupId":"OG001","value":"665.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null},{"groupId":"OG001","value":"131.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"88.0","spread":null}]}]}]},{"type":"PRIMARY","title":"GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 Dengue Serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223.9","spread":null},{"groupId":"OG001","value":"366.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129.9","spread":null},{"groupId":"OG001","value":"425.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"114.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":null},{"groupId":"OG001","value":"55.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"573.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190.6","spread":null},{"groupId":"OG001","value":"401.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"215.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"88.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":null},{"groupId":"OG001","value":"73.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"67.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null},{"groupId":"OG001","value":"95.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null},{"groupId":"OG001","value":"77.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"72.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"59.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"71.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"67.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"63.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"96.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"96.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null},{"groupId":"OG001","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"96.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Each of the 4 Dengue Serotypes at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"94.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"59.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":null},{"groupId":"OG001","value":"65.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"25.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"48.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 1 Month Post-Booster Dose at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 3, pre-booster dose for all participants (Month 15 for parent trial DEN-304 and Month 42 for parent trial DEN-315). Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null},{"groupId":"OG001","value":"58.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4, 1 month post-booster dose for all participants (Month 16 for parent trial DEN-304 and Month 43 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 15) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\ any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 15 for participants from parent trial DEN-304. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"63.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 16) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), \\\\any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 16 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at Pre-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 3 (Month 42) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the pre-booster data from Visit 3 at Month 42 for participants from parent trial DEN-315. Pre-booster dose is defined as the last non-missing value before booster administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes at 1 Month Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 4 (Month 43) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 4 at Month 43 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose at Visit 5 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"92.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-booster Dose at 6 Months Post-Booster Dose at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 for Both Parent Trials","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5, 6 month post-booster dose for all participants (Month 21 for parent trial DEN-304 and Month 48 for parent trial DEN-315).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-Booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 21) (DEN-304)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 21 for participants from parent trial DEN-304.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null},{"groupId":"OG001","value":"95.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Seropositivity Rate for Multiple (2, 3 or 4) Dengue Serotypes Post-booster Dose at 6 Months Post-Booster Dose by Serostatus at Baseline in the Parent Trials at Visit 5 (Month 48) (DEN-315)","description":"Seropositivity rate for multiple Dengue serotypes, defined as the percentage of participants seropositive for more than one Dengue serotype, is derived from the titers of dengue-neutralizing antibodies. All 4 dengue serotypes (tetravalent), any 2 of the 4 dengue serotypes (bivalent), any 3 of the 4 dengue serotypes (trivalent). Seropositivity is defined as a reciprocal neutralizing titer ≥10. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Reported here is the data from Visit 5 at Month 48 for participants from parent trial DEN-315.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"94.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for All Participants Prior to the Booster Dose","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.753","spread":null},{"groupId":"OG001","value":"0.891","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.698","spread":null},{"groupId":"OG001","value":"0.622","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.864","spread":null},{"groupId":"OG001","value":"0.852","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.689","spread":null},{"groupId":"OG001","value":"0.861","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.438","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.275","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.296","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.066","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.529","spread":null},{"groupId":"OG001","value":"0.517","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.396","spread":null},{"groupId":"OG001","value":"0.466","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.440","spread":null},{"groupId":"OG001","value":"0.547","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.577","spread":null},{"groupId":"OG001","value":"0.568","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.415","spread":null},{"groupId":"OG001","value":"0.486","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.265","spread":null},{"groupId":"OG001","value":"0.289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.407","spread":null},{"groupId":"OG001","value":"0.435","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.384","spread":null},{"groupId":"OG001","value":"0.567","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes by Serostatus at Baseline in the Parent Trials Prior to the Booster Dose","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.736","spread":null},{"groupId":"OG001","value":"0.705","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","spread":null},{"groupId":"OG001","value":"0.456","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.980","spread":null},{"groupId":"OG001","value":"1.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.736","spread":null},{"groupId":"OG001","value":"0.727","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.506","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.178","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.393","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.319","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.070","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.635","spread":null},{"groupId":"OG001","value":"0.528","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.469","spread":null},{"groupId":"OG001","value":"0.454","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.538","spread":null},{"groupId":"OG001","value":"0.556","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.710","spread":null},{"groupId":"OG001","value":"0.684","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.497","spread":null},{"groupId":"OG001","value":"0.375","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.311","spread":null},{"groupId":"OG001","value":"0.172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.561","spread":null},{"groupId":"OG001","value":"0.664","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.577","spread":null},{"groupId":"OG001","value":"0.966","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","spread":null},{"groupId":"OG001","value":"0.900","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.689","spread":null},{"groupId":"OG001","value":"0.630","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.847","spread":null},{"groupId":"OG001","value":"0.846","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.681","spread":null},{"groupId":"OG001","value":"0.867","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.427","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.265","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.223","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.192","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.065","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.514","spread":null},{"groupId":"OG001","value":"0.516","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.385","spread":null},{"groupId":"OG001","value":"0.467","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.426","spread":null},{"groupId":"OG001","value":"0.547","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.557","spread":null},{"groupId":"OG001","value":"0.560","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.403","spread":null},{"groupId":"OG001","value":"0.492","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.259","spread":null},{"groupId":"OG001","value":"0.296","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.387","spread":null},{"groupId":"OG001","value":"0.426","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.359","spread":null},{"groupId":"OG001","value":"0.553","spread":null}]}]}]},{"type":"SECONDARY","title":"GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Booster Phase","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.352","spread":null},{"groupId":"OG001","value":"4.298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.124","spread":null},{"groupId":"OG001","value":"0.378","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.231","spread":null},{"groupId":"OG001","value":"3.042","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.136","spread":null},{"groupId":"OG001","value":"1.505","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.285","spread":null},{"groupId":"OG001","value":"1.409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.100","spread":null},{"groupId":"OG001","value":"0.206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.225","spread":null},{"groupId":"OG001","value":"1.133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.110","spread":null},{"groupId":"OG001","value":"0.468","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.817","spread":null},{"groupId":"OG001","value":"0.334","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.825","spread":null},{"groupId":"OG001","value":"0.535","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.990","spread":null},{"groupId":"OG001","value":"0.370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.842","spread":null},{"groupId":"OG001","value":"0.323","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.962","spread":null},{"groupId":"OG001","value":"11.762","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.936","spread":null},{"groupId":"OG001","value":"2.822","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.856","spread":null},{"groupId":"OG001","value":"14.889","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.977","spread":null},{"groupId":"OG001","value":"13.162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.784","spread":null},{"groupId":"OG001","value":"3.810","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.763","spread":null},{"groupId":"OG001","value":"1.550","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.858","spread":null},{"groupId":"OG001","value":"5.622","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.808","spread":null},{"groupId":"OG001","value":"4.289","spread":null}]}]}]},{"type":"SECONDARY","title":"GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes by Serostatus at Baseline in the Parent Trials in the Booster Phase","description":"The geometric mean ratio is the geometric mean of the ratio of the two visits being compared. Baseline seropositivity is defined as reciprocal neutralizing titer ≥10 for one or more dengue serotypes at baseline in the parent trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.413","spread":null},{"groupId":"OG001","value":"2.219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.118","spread":null},{"groupId":"OG001","value":"0.355","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.311","spread":null},{"groupId":"OG001","value":"1.566","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.187","spread":null},{"groupId":"OG001","value":"1.018","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.033","spread":null},{"groupId":"OG001","value":"3.683","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.803","spread":null},{"groupId":"OG001","value":"1.805","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.825","spread":null},{"groupId":"OG001","value":"3.699","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.310","spread":null},{"groupId":"OG001","value":"5.895","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.065","spread":null},{"groupId":"OG001","value":"1.404","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.739","spread":null},{"groupId":"OG001","value":"0.906","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.965","spread":null},{"groupId":"OG001","value":"1.544","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.871","spread":null},{"groupId":"OG001","value":"1.923","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.998","spread":null},{"groupId":"OG001","value":"0.379","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.026","spread":null},{"groupId":"OG001","value":"0.506","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.024","spread":null},{"groupId":"OG001","value":"0.437","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.772","spread":null},{"groupId":"OG001","value":"0.349","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.400","spread":null},{"groupId":"OG001","value":"0.779","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.103","spread":null},{"groupId":"OG001","value":"0.161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.333","spread":null},{"groupId":"OG001","value":"0.593","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.113","spread":null},{"groupId":"OG001","value":"0.314","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.343","spread":null},{"groupId":"OG001","value":"4.692","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.125","spread":null},{"groupId":"OG001","value":"0.382","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.221","spread":null},{"groupId":"OG001","value":"3.322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.130","spread":null},{"groupId":"OG001","value":"1.585","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.953","spread":null},{"groupId":"OG001","value":"13.646","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.956","spread":null},{"groupId":"OG001","value":"2.988","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.860","spread":null},{"groupId":"OG001","value":"17.792","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.939","spread":null},{"groupId":"OG001","value":"14.586","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","spread":null},{"groupId":"OG001","value":"4.425","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.766","spread":null},{"groupId":"OG001","value":"1.680","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.846","spread":null},{"groupId":"OG001","value":"6.824","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.801","spread":null},{"groupId":"OG001","value":"4.837","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.799","spread":null},{"groupId":"OG001","value":"0.328","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.805","spread":null},{"groupId":"OG001","value":"0.539","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.986","spread":null},{"groupId":"OG001","value":"0.361","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.850","spread":null},{"groupId":"OG001","value":"0.319","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.273","spread":null},{"groupId":"OG001","value":"1.546","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.100","spread":null},{"groupId":"OG001","value":"0.214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.215","spread":null},{"groupId":"OG001","value":"1.253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.109","spread":null},{"groupId":"OG001","value":"0.498","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post-Booster Vaccination","description":"Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days post-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315). AEs were graded by the investigator in the following manner: Mild: Grade 1: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment; Moderate: Grade 2: Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment; Severe: Grade 3: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities. Not relieved with symptomatic treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Systemic Adverse Events Within 14 Days Post-Booster Vaccination by Severity","description":"Solicited systemic AEs are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days post-booster dose at Month 15 (DEN-304) and Month 42 (DEN-315). AEs were graded by the investigator in the following manner: Mild: Grade 1: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities. Relieved with or without symptomatic treatment; Moderate: Grade 2: Sufficient discomfort is present to cause interference with normal activity. Only partially relieved with symptomatic treatment; Severe: Grade 3: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities. Not relieved with symptomatic treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Unsolicited AEs in the Booster Phase","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Medically Attended AEs (MAAEs) in the Booster Phase","description":"MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Serious Adverse Events (SAEs) Prior to the Booster Dose","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any SAEs in the Booster Phase","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine or placebo; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":246},"commonTop":["Pain","Headache","Myalgia","Malaise","Asthenia"]}}}